The role of tumor progression locus 2 protein kinase in glial inflammatory response

Joshua Hirschhorn1, Sangeeta Mohanty, Narayan R Bhat

  • 1Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina, USA.

Journal of Neurochemistry
|November 6, 2013
PubMed

Insights

Tumor progression locus 2 (Tpl2) kinase activates inflammatory responses in glial cells. Inhibiting Tpl2 reduces pro-inflammatory cytokine release and inducible nitric oxide synthase expression, highlighting its role in glial inflammation.

Area of Science:

  • Neuroimmunology
  • Cellular signaling pathways
  • Molecular biology

Background:

  • Tumor progression locus 2 (Tpl2) is a MAP3K family member crucial for TNFα expression in macrophages.
  • The pro-inflammatory signaling role of Tpl2 in glial cells remains largely uncharacterized.

Purpose of the Study:

  • To investigate the role and signaling function of Tpl2 in glial cells, specifically microglia and astrocytes.
  • To determine if Tpl2 activation influences the inflammatory response in glia.

Main Methods:

  • Murine microglia and astrocyte cultures were stimulated with lipopolysaccharide.
  • Tpl2 activation and downstream MAPK pathways (ERK, p38, JNK) were assessed.
  • Tpl2 inhibitor effects on cytokine release and iNOS expression were evaluated.
  • Tpl2 gain-of-function and loss-of-function studies were performed in C-6 glia.

Main Results:

  • LPS stimulation rapidly activated Tpl2 and downstream MAPKs (ERK, p38, JNK) in glial cells.
  • A Tpl2 inhibitor selectively suppressed ERK activation and reduced TNFα release and iNOS expression.
  • Overexpression of wild-type Tpl2 enhanced iNOS transcription, while dominant-negative Tpl2 inhibited it.

Conclusions:

  • Tpl2 plays a significant pro-inflammatory signaling role in glial cells.
  • The Tpl2 pathway is involved in regulating cytokine release and iNOS expression in glia.
  • Tpl2 represents a potential therapeutic target for neuroinflammatory conditions.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.3K